Antibiotics Help Schizophrenia, Depression, Alzheimer's, etc. ... James Schaller Asks, Why is this a Surprise?
Why are scientists shocked at yet another strong benefit from an antibiotic helping schizophrenia? In ten papers alone over 100 infections are implicated in depression, dementia, autism, bipolar, schizophrenia, etc.
Scientists believe that schizophrenia and other mental illnesses including depression and Alzheimer's disease may result from inflammatory processes in the brain. Minocycline has anti-inflammatory and neuroprotective effects which they believe could account for the positive findings. Of course this is a guess and scientists have no clue which of the many reasons or actions is the effect. In some Northern European countries Bartonella and Lyme disease are common and felt to be trivial—but spirochetes and mental illness is clear and Bartonella is a massive psychiatric disease maker (For example, James Schaller. Medscape article). I look at many inflammation markers and many people with these psychiatric troubles do not have clear or severe inflammation.
So yet again minocycline helps schizophrenia and this is a stunner—why?
We are not bubble people and the tens of thousands of infectious entities we are exposed to are in excess of all of human knowledge. We are at least 50 years from handling many routine infection troubles, so acting as if we have infections covered is immensely false science and deceptive medicine.
Jeremy Laurence adds yet another example in reporting cheap minocycline at times used for acne is to be tested as a treatment to alleviate the symptoms of psychosis in patients with schizophrenia. Indeed, the National Institute for Health Research is funding a £1.9m trial of minocycline, which will begin recruiting patients in the UK next month and may be based in part on Japan's experience—the drug was prescribed to schizophrenia patients who had "infections" and they experienced a dramatic improvements in their psychotic symptoms. Trials in Israel, Pakistan and Brazil have shown significant improvement in patients treated with the drug.
The first account of minocycline's effects appeared in 2007 when a 23-year-old Japanese man was admitted to hospital suffering from persecutory delusions and paranoid ideas. He had no previous psychiatric history but became agitated and suffered auditory hallucinations, anxiety and insomnia. Haldol did not help, but minocycline for his severe pneumonia ended his severe psychosis in two weeks.
Professor Sir Robin Murray, chair of the Schizophrenia Commission said: "Infection or inflammation might be involved in a minority of people with acute psychosis and minocycline might counter this. In depression inflammatory markers go up and in Alzheimer's too." So here is my basic question—why are the very simple and very basic inflammatory markers used in psychiatric research ever high? Something makes them high.